JP2019502694A5 - - Google Patents

Download PDF

Info

Publication number: JP2019502694A5
Authority: JP; Japan
Prior art keywords: domain; amino acid; acid sequence; polypeptide; seq
Prior art date: 2016-12-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2018531487A

Other languages

English (en)

Japanese (ja)

Other versions

JP2019502694A (ja

JP7138046B2 (ja

Filing date

2016-12-15

Publication date

2020-01-16

2016-12-15 Application filed filed Critical

2016-12-15 Priority claimed from PCT/US2016/066865 external-priority patent/WO2017106462A1/en

2019-01-31 Publication of JP2019502694A publication Critical patent/JP2019502694A/ja

2020-01-16 Publication of JP2019502694A5 publication Critical patent/JP2019502694A5/ja

2021-06-01 Priority to JP2021092180A priority Critical patent/JP2021121642A/ja

2022-09-15 Application granted granted Critical

2022-09-15 Publication of JP7138046B2 publication Critical patent/JP7138046B2/ja

Status Active legal-status Critical Current

2036-12-15 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 372
229920001184 polypeptide Polymers 0.000 claims description 365
102000004196 processed proteins & peptides Human genes 0.000 claims description 365
125000003275 alpha amino acid group Chemical group 0.000 claims description 310
235000001014 amino acid Nutrition 0.000 claims description 185
229940024606 amino acid Drugs 0.000 claims description 176
150000001413 amino acids Chemical class 0.000 claims description 146
239000000427 antigen Substances 0.000 claims description 116
102000036639 antigens Human genes 0.000 claims description 116
108091007433 antigens Proteins 0.000 claims description 116
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 65
238000005734 heterodimerization reaction Methods 0.000 claims description 56
239000012634 fragment Substances 0.000 claims description 37
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 31
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 24
239000004472 Lysine Substances 0.000 claims description 24
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 14
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
230000004988 N-glycosylation Effects 0.000 claims description 14
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 14
239000004473 Threonine Substances 0.000 claims description 14
125000000539 amino acid group Chemical group 0.000 claims description 14
229960001230 asparagine Drugs 0.000 claims description 14
235000009582 asparagine Nutrition 0.000 claims description 14
239000000539 dimer Substances 0.000 claims description 13
108060003951 Immunoglobulin Proteins 0.000 claims description 11
229940094342 human immunoglobulin m Drugs 0.000 claims description 11
102000018358 immunoglobulin Human genes 0.000 claims description 11
230000035772 mutation Effects 0.000 claims description 9
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
235000018417 cysteine Nutrition 0.000 claims description 7
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 6
229960000310 isoleucine Drugs 0.000 claims description 6
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
229920001223 polyethylene glycol Polymers 0.000 claims description 6
102000008100 Human Serum Albumin Human genes 0.000 claims description 3
108091006905 Human Serum Albumin Proteins 0.000 claims description 3
239000000833 heterodimer Substances 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims 4
238000000034 method Methods 0.000 description 9
238000004587 chromatography analysis Methods 0.000 description 2
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1

JP2018531487A 2015-12-18 2016-12-15 二特異性抗体基幹 Active JP7138046B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2021092180A JP2021121642A (ja)	2015-12-18	2021-06-01	二特異性抗体基幹

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562269664P	2015-12-18	2015-12-18
US62/269,664		2015-12-18
PCT/US2016/066865 WO2017106462A1 (en)	2015-12-18	2016-12-15	Bispecific antibody platform

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021092180A Division JP2021121642A (ja)	2015-12-18	2021-06-01	二特異性抗体基幹

Publications (3)

Publication Number	Publication Date
JP2019502694A JP2019502694A (ja)	2019-01-31
JP2019502694A5 true JP2019502694A5 (2)	2020-01-16
JP7138046B2 JP7138046B2 (ja)	2022-09-15

Family

ID=57681809

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2018531487A Active JP7138046B2 (ja)	2015-12-18	2016-12-15	二特異性抗体基幹
JP2021092180A Pending JP2021121642A (ja)	2015-12-18	2021-06-01	二特異性抗体基幹

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2021092180A Pending JP2021121642A (ja)	2015-12-18	2021-06-01	二特異性抗体基幹

Country Status (9)

Country	Link
US (1)	US11447575B2 (2)
EP (1)	EP3389710A1 (2)
JP (2)	JP7138046B2 (2)
KR (1)	KR20180100136A (2)
CN (1)	CN108601830B (2)
AU (1)	AU2016370821A1 (2)
CA (1)	CA3008840A1 (2)
MA (1)	MA44054A (2)
WO (1)	WO2017106462A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201901557XA (en) *	2016-08-26	2019-03-28	Sanofi Sa	Multispecific antibodies facilitating selective light chain pairing
EP3661555B1 (en)	2017-08-01	2025-04-16	Ab Therapeutics, Inc.	Bispecific antibodies and uses thereof
CN110028588A (zh) *	2018-01-11	2019-07-19	上海细胞治疗研究院	抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
CN113508135A (zh)	2018-10-29	2021-10-15	比奥根Ma公司	增强血脑屏障转运的人源化和稳定化的fc5变体
CA3120800A1 (en)	2018-12-17	2020-06-25	Revitope Limited	Twin immune cell engager
WO2020159918A2 (en)	2019-01-28	2020-08-06	Ab Therapeutics, Inc.	Bispecific antibodies and uses thereof
US20220227827A1 (en) *	2019-03-25	2022-07-21	Dingfu Biotarget Co., Ltd.	Proteinaceous heterodimer and use thereof
CN114302893B (zh) *	2019-08-15	2025-01-28	瑞泽恩制药公司	用于细胞靶向的多特异性抗原结合分子及其用途
KR20220050166A (ko) *	2019-08-23	2022-04-22	아이쥐엠 바이오사이언스 인코포레이티드	Igm 글리코변이체
JP2022550316A (ja) *	2019-09-25	2022-12-01	ウニヴェルズィテートシュトゥットガルト	修飾ｅｈｄ２ドメインを含む結合モジュール
CA3164979A1 (en) *	2020-01-09	2021-07-15	Jiangsu Hengrui Medicine Co., Ltd.	New polypeptide complex
CN113307879A (zh) *	2020-02-27	2021-08-27	启愈生物技术(上海)有限公司	一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) *	2020-04-29	2021-10-29	三生国健药业（上海）股份有限公司	四价双特异性抗体、其制备方法和用途
IL301926A (en) *	2020-11-06	2023-06-01	Amgen Inc	Antigen binding domain with reduced clipping rate
CA3219388A1 (en) *	2021-05-14	2022-11-17	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen-binding molecule
WO2023010060A2 (en)	2021-07-27	2023-02-02	Novab, Inc.	Engineered vlrb antibodies with immune effector functions
KR20250075665A (ko) *	2022-09-28	2025-05-28	드렌 바이오, 인크.	다중특이적 항체 및 이의 사용 방법
WO2025042806A2 (en)	2023-08-21	2025-02-27	Modernatx, Inc.	C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2026044055A1 (en)	2024-08-23	2026-02-26	Modernatx, Inc.	Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en)	2024-10-03	2026-04-09	Modernatx, Inc.	4-1bb binding molecules, nucleic acids encoding same, and methods of use
CN121148519B (zh) *	2025-11-18	2026-02-13	西北农林科技大学	基于计算模拟辅助的双特异性抗体分子设计与优化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090162359A1 (en) *	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
JP5768147B2 (ja) *	2011-02-28	2015-08-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	一価抗原結合タンパク質
US9738707B2 (en) *	2011-07-15	2017-08-22	Biogen Ma Inc.	Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013156054A1 (en)	2012-04-16	2013-10-24	Universität Stuttgart	The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2855531A1 (en) *	2012-05-24	2015-04-08	F. Hoffmann-La Roche AG	Multispecific antibodies
WO2015058048A1 (en) *	2013-10-18	2015-04-23	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
ES2935274T3 (es) *	2014-12-05	2023-03-03	Merck Patent Gmbh	Anticuerpo con intercambio de dominios
WO2017011342A1 (en)	2015-07-10	2017-01-19	Abbvie Inc.	Igm-or-ige-modified binding proteins and uses thereof
SG11201901557XA (en) *	2016-08-26	2019-03-28	Sanofi Sa	Multispecific antibodies facilitating selective light chain pairing
CA3120800A1 (en) *	2018-12-17	2020-06-25	Revitope Limited	Twin immune cell engager

2016
- 2016-12-15 CN CN201680081272.6A patent/CN108601830B/zh active Active
- 2016-12-15 US US16/061,903 patent/US11447575B2/en active Active
- 2016-12-15 MA MA044054A patent/MA44054A/fr unknown
- 2016-12-15 KR KR1020187020661A patent/KR20180100136A/ko not_active Abandoned
- 2016-12-15 WO PCT/US2016/066865 patent/WO2017106462A1/en not_active Ceased
- 2016-12-15 EP EP16820131.7A patent/EP3389710A1/en active Pending
- 2016-12-15 AU AU2016370821A patent/AU2016370821A1/en not_active Abandoned
- 2016-12-15 JP JP2018531487A patent/JP7138046B2/ja active Active
- 2016-12-15 CA CA3008840A patent/CA3008840A1/en active Pending
2021
- 2021-06-01 JP JP2021092180A patent/JP2021121642A/ja active Pending

Publication	Publication Date	Title
JP2019502694A5 (2)	2020-01-16
JP2017504578A5 (2)	2017-09-28
JP2016527314A5 (2)	2017-09-07
JP6606505B2 (ja)	2019-11-13	抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
JP2020508655A5 (2)	2021-02-12
HRP20210739T1 (hr)	2021-06-25	Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada
JP2017504577A5 (2)	2017-09-28
US20170210818A1 (en)	2017-07-27	Constant region antibody fusion proteins and compositions thereof
JP2021503455A5 (2)	2021-12-09
JP2020524510A5 (2)	2021-07-29
JP2017522891A5 (2)	2018-09-06
US20220340677A1 (en)	2022-10-27	Split intein and preparation method for recombinant polypeptide using the same
JP2021522162A5 (2)	2022-04-25
JP2016525551A5 (2)	2017-12-28
RU2016108703A (ru)	2017-09-14	Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
JP2019512207A5 (2)	2020-02-20
HRP20200390T1 (hr)	2020-06-12	Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2017536128A (ja)	2017-12-07	ドメイン交換抗体
JP2010539921A5 (2)	2011-11-10
WO2018119118A4 (en)	2018-08-16	Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
RU2015144098A (ru)	2017-04-21	Четырехвалентные биспецифические антитела
JP2014158485A5 (2)	2015-06-11
JP2014519322A5 (2)	2015-07-02
HRP20201191T1 (hr)	2020-11-13	Mutirani multispecifični fab fragmenti antitijela
JP2018522888A5 (2)	2019-07-04